Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on April 12, 2006
Japanese Journal of Clinical Oncology 2006 36(4):207-211; doi:10.1093/jjco/hyl004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/4/207    most recent
hyl004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Inoh, K.
Right arrow Articles by Muramatsu, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inoh, K.
Right arrow Articles by Muramatsu, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2006 Foundation for Promotion of Cancer Research

Doxorubicin-Conjugated Anti-Midkine Monoclonal Antibody as a Potential Anti-Tumor Drug

Kazuhiko Inoh1,2, Hisako Muramatsu3, Shuhei Torii2, Shinya Ikematsu4, Munehiro Oda4, Hideshi Kumai4, Sadatoshi Sakuma5, Tatsuya Inui6, Terutoshi Kimura6 and Takashi Muramatsu1

1 Department of Biochemistry, 2 Department of Plastic Surgery and 3 Division of Disease Models, Center for Neural Disease and Cancer, Nagoya University Graduate School of Medicine, Nagoya, 4 Meiji Milk Co Ltd, Odawara, Kanagawa, 5 Cell Signals Inc., Yokohama and 6 Peptide Institute, Minoh, Osaka, Japan

For reprints and all correspondence: Hisako Muramatsu, Department of Biochemistry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. E-mail: hmurama{at}med.nagoya-u.ac.jp

Received November 24, 2003; accepted December 28, 2005

Background: Midkine is a heparin-binding growth factor preferentially expressed in tumor cells. The present study was performed to utilize anti-midkine antibody for tumor therapy.

Methods: A monoclonal antibody to midkine was raised by immunizing mice deficient in the midkine gene. The binding site of the antibody was studied by using N-terminal half and C-terminal half of midkine, both of which were chemically synthesized. Doxorubicin (DOX)-conjugate of the antibody was produced by chemical conjugation. The effects of the antibody and the conjugate on cell growth were examined using a midkine-secreting tumor cell, i.e. human hepatocellular carcinoma cell (HepG2).

Results: The monoclonal antibody bound to the N-terminal half of midkine. The antibody did not inhibit the growth of HepG2 cells probably because the active domain of midkine is in the C-terminal half. We produced the antibody conjugated with DOX with the hope that the conjugate would be internalized accompanied with midkine. Indeed, the antibody-DOX conjugate significantly inhibited the growth of HepG2 cells compared with DOX-conjugated control IgG.

Conclusion: The result raises the possibility of using anti-midkine antibody conjugated with DOX for cancer therapy.

Key Words: antibody – monoclonal – cancer – growth substances – immunotoxins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.